Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Mounjaro process in the UK involves three fixed steps: a clinical consultation, a prescription issued by a registered prescriber, and dispensing through a GPhC-registered pharmacy. Because tirzepatide is a Prescription-Only Medicine, no one can legally supply it without a prescriber first assessing whether it is appropriate for you specifically. That assessment considers your BMI, any weight-related conditions, your medical history, and the medicines you already take — not just a self-reported BMI tick-box. Once approved as clinically suitable, treatment is dispensed and delivered; at nume, that typically means same-day dispatch and next-working-day arrival.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is where a lot of people expect a rubber stamp, and it isn't. The consultation is a structured clinical questionnaire (covering your current weight, height, relevant medical history, existing medications, and any contraindications) reviewed in full by a GPhC-registered Independent Prescriber. At nume, that review happens the same day; a named clinician reads your answers, not a piece of software. Our prescribers follow the licensed eligibility criteria: adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. If you are transferring from another provider or requesting a dose increase, you will be asked to provide evidence of your current treatment and recent weight. The consultation also includes photo-ID verification and a live weight check via video, because a prescription for a controlled clinical treatment needs to be based on real data, not self-reported figures. You can read more about our clinical team and how these decisions are made. The whole stage is free of charge.
Once the prescriber is satisfied that Mounjaro is the right treatment for you, they issue a UK private prescription. That prescription goes directly to the GPhC-registered pharmacy, ours holds registration number 9012878, verifiable at the GPhC pharmacy register. The pharmacy dispenses the correct pen from the licensed UK supply chain, checks stock, labels the prescription, and prepares it for dispatch. Medicines sourced through the licensed UK supply chain come from Eli Lilly, the company that produces Mounjaro, via their authorised distribution network; they are not grey-market imports or repackaged stock from other markets. If you order by 12 pm on a working day and the prescriber approves your consultation that same day, your pen is dispatched the same afternoon. Delivery is free, tracked, and carried out by DPD in plain, unbranded packaging, it arrives the next working day. The prescription, the clinical review, and the delivery are all included in the single treatment price; there are no separate consultation fees or delivery charges added at checkout. A useful point of comparison is available if you want to see how UK Mounjaro costs are structured across providers.
Tirzepatide's licensed schedule in the UK starts at 2.5 mg. The opening dose exists to let your body adjust to the medicine's effects on gastric emptying and appetite, it is a settling-in period, and nausea or digestive changes at this stage are normal and usually temporary. The prescriber, not the patient, decides when and whether to move to the next strength. Typical titration runs in four-week intervals, stepping through 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and up to 15 mg, with each step conditional on tolerability and clinical appropriateness. If you are weighing up which strength to start on, it helps to understand how Mounjaro is priced at each dose level, so you can plan your treatment budget from the outset. The NHS patient information page for tirzepatide has a clear summary of the standard dosing schedule, and the full prescribing detail lives in the medicine's Summary of Product Characteristics on the eMC. You should never self-titrate or skip steps based on advice found online; the prescriber's judgement is the only appropriate guide here. Our FAQs page covers some of the most common questions about dose progression.
Mounjaro is not a one-and-done treatment. The clinical process continues with every repeat order, at nume, no prescription is renewed automatically. Before each repeat, the prescriber reviews whether continuing is appropriate: this typically involves checking your current weight, any side effects you have experienced, and whether your dose should stay the same or move up. Many patients also find it helpful to review the Mounjaro orices for ongoing treatment so there are no surprises as they progress through the titration schedule. NICE's guidance on tirzepatide, published as TA1026, notes that continuing treatment should be reviewed if less than 5% weight loss has been achieved after six months at the highest tolerated dose. That kind of checkpoint is built into responsible clinical practice. Aftercare support is available seven days a week at nume, if you have a question between orders, there is a real team to contact via our contact page. Treatment sits alongside, not instead of, dietary changes and increased activity; the prescriber will factor lifestyle context into their review. For a broader picture of how tirzepatide fits into the UK weight-management landscape, the tirzepatide overview is a good starting point, and the weight-loss treatment overview sets out the options available through nume. When you are ready to begin, you can start your free consultation with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.